01366nas a2200265   4500000000100000008004100001260001300042653001000055653004100065653001200106653001100118653002500129653001600154100001300170700001200183700001300195700001000208700001500218700001100233245008500244300001000329490000700339520074000346022001401086       1988                            d  c1988 Nov10aAdult10aChromatography, High Pressure Liquid10aDapsone10aHumans10aLeprosy, lepromatous10aMiddle Aged1 aGarg S K1 aKumar B1 aBakaya V1 aLal R1 aShukla V K1 aKaur S00aPlasma dapsone and its metabolite monoacetyldapsone levels in leprotic patients.  a552-40 v263 a<p>Dapsone (DDS) is a drug of choice in the treatment of leprosy. The DDS and MADDS levels and different pharmacokinetic parameters after a single dose of dapsone and at steady state in leprotic patients have been studied. At steady state, all the patients showed plasma DDS and MADDS levels above 0.5 micrograms/ml throughout the 24-h duration. There was no significant difference in the elimination half-lives of DDS and MADDS after a single dose as compared to at steady state, but AUC0-alpha for both DDS and MADDS were significantly increased at steady state. From these results, it could be concluded that 100 mg daily dose is sufficient to maintain plasma therapeutic concentration in leprotic patients in Indian population.</p>  a0174-4879